Cas9-specific antibodies and reactive T cells are found in the majority of healthy adult human serum samples analyzed. Such preexisting adaptive immunity should be taken into consideration as the CRISPR–Cas9 system moves toward clinical trials.
- Carsten T. Charlesworth
- Priyanka S. Deshpande
- Matthew H. Porteus
